![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » GlaxoSmithKline India to Begin Vaccines Production in 2006
GlaxoSmithKline India to Begin Vaccines Production in 2006
The Indian affiliate of UK-based drug major GlaxoSmithKline, GSK India, has announced plans to begin vaccines production in the country at a new facility by early 2006. The company, which also recently announced that it would seek to make a limited number of generic medicines in the country, would invest about INR1bn (US$22.87mn) at the new site, replacing production at its parent's world vaccines centre in Belgium, GSK Biologicals.
GSK India, 49.2% owned by its UK parent, currently has a limited but fast-expanding research portfolio which could receive a boost from the transfer of vaccines production. GSK has recently launched a vaccine for rotavirus-related gastroenteritis, and has additional leading products inoculating against malaria, tubercolosis, dengue fever, Hepatitis E and Typhoid.
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
18Jul
-
21Oct